LNP023 monotherapy

Study of efficacy and safety of LNP023 (iptacopan) in patients >= 18 years of age diagnosed with atypical hemolytic uremic syndrome who have never received treatment with complement inhibitors

A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy